A prospective, randomized trial of integrative medicine for women with ovarian cancer.
A prospective, randomized trial of integrative medicine for women with ovarian cancer.
复制标题
DOI：
10.1016/j.ygyno.2011.07.099
复制
发表时间：
2011-11
影响因子：
4.7
通讯作者：
Downs LS Jr
中科院分区：
文献类型：
--
作者：
Judson PL;Dickson EL;Argenta PA;Xiong Y;Geller MA;Carson LF;Ghebre R;Jonson AL;Downs LS Jr
尽管在癌症治疗中越来越多地使用中西医结合，但关于其疗效的数据很少。这项前瞻性、随机性、先导性试验旨在评估联合模式综合药物(CM-IM)治疗卵巢癌(OvCA)的可行性，并评估其对生活质量(QOL)、化疗毒性和免疫学特征的影响。新诊断为OvCA需要化疗的妇女被提供参加。那些被随机分配到试验组的人在每个化疗周期中都会接受催眠、治疗性按摩和治愈触摸。对照组接受不含CM-IM的化疗。所有患者在化疗前1、3、6周期及化疗后6个月完成生活质量问卷调查。测定免疫学指标。统计分析以意向治疗为基础。采用t检验和Fischer‘s精确检验进行统计学处理。43名女性参加了这项活动。所有随机接受CM-IM的妇女都得到了成功的治疗。在年龄、分期、分级、组织细胞类型、CA125水平或手术细胞减少状态方面，两组之间没有统计学差异。在总体生活质量测量方面没有差异。再住院率、治疗延误、止吐用药和感染率相似。免疫学资料显示，WBC或唾液IgA水平在ARMS之间没有差异。接受CM-IM的女性的CD4、CD8和NK细胞水平一直较高，尽管这一水平没有达到统计学意义。中西医结合治疗妇科恶性肿瘤的前瞻性临床评价是可行的。这是CM-IM在妇科肿瘤学中的第一项先导性研究，显示其在生活质量或化疗毒性方面没有改善。与中西医结合相关的免疫学方面的改善值得进一步研究。
Despite increased use of integrative medicine in cancer therapy, little data exist on its efficacy. This prospective, randomized, pilot trial sought to evaluate the feasibility of combined modality integrative medicine (CM-IM) in women with ovarian cancer (OvCA) and evaluate its effects on quality of life (QoL), chemotherapy toxicity and immunologic profiles. Women with newly diagnosed OvCA requiring chemotherapy were offered enrollment. Those randomized to the experimental arm received hypnosis, therapeutic massage and healing touch with each cycle of chemotherapy. The control arm received chemotherapy without CM-IM. All patients completed QoL questionnaires prior to cycles 1, 3 and 6, and 6-months after chemotherapy. Immunologic profiles were measured. Statistical analysis was based on intent-to-treat. Student’s t-test and Fischer’s exact-test were used to determine differences. Forty-three women enrolled. All women randomized to CM-IM were successfully treated. There were no statistical differences between the groups in age, stage, grade, histologic cell type, CA125 levels, or surgical cytoreductive status. There was no difference in overall QoL measurements. Re-hospitalization rates, treatment delays, anti-emetic use, and infection rates were similar. Immunologic profiles revealed no difference between arms for WBC or salivary IgA levels. Women receiving CM-IM had consistently higher levels of CD4, CD8 and NK cells, although this did not reach statistical significance. Prospective clinical evaluation of integrative medicine for women with gynecologic malignancy is feasible. This first, pilot study of CM-IM in gynecologic oncology demonstrated no improvement in QoL or chemotherapy toxicity. Integrative medicine-associated improvements in immunologic profiles warrant further investigation.
登录
查看更多内容
影响因子：
4.7
作者：
von Gruenigen, Vivian E.;Frasure, Heidi E.;Gil, Karen M.
通讯作者：
Gil, Karen M.
影响因子：
3.1
作者：
Fasching, P. A.;Thiel, F.;Bani, M. R.
通讯作者：
Bani, M. R.
影响因子：
2.9
作者：
Post-White, Janice;Kinney, Mary Ellen;Lerner, Irving
通讯作者：
Lerner, Irving
影响因子：
5.8
作者：
Holcombe, RF;Jacobson, J;Macdonald, JS
通讯作者：
Macdonald, JS
影响因子：
45.3
作者：
CELLA, DF;TULSKY, DS;HARRIS, J
通讯作者：
HARRIS, J